Languages  By theme  By sector  By country
Page : 1 - 2 - ... 6 - 7 - 8 - 9 - 10 - 11 - 12 - ...
SANOFI-AVENTIS [FR0000120578/SAN]   
[03/05/2013]

SANOFI-AVENTIS : Combined General Shareholder Meeting of May 3, 2013

PRESS RELEASE Combined General Shareholder Meeting of May 3, 2013 * Shareholder approval of the financial statements for 2012 * Dividend of EUR2.77 per share payable as of May 14, 2013 * Nomination of a new director, Ms. Fabienne Lecorvaisier Paris, France - May 3, 2013 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[02/05/2013]

SANOFI-AVENTIS : Q1 2013 business EPS impacted by exclusivity losses in prior year - Growth platforms sales increased 8.6%

PRESS RELEASE Paris, May 2, 2013 Q1 2013 business EPS1 impacted by exclusivity losses in prior year Growth platforms2 sales increased 8.6%3 ... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[02/05/2013]

SANOFI-AVENTIS : Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization

PRESS RELEASE Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization Paris, France - May 2, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today a new commercial organization to better align with its business priorities. The past four years have seen a significant shift within the company to become an... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[25/04/2013]

SANOFI-AVENTIS : Sanofi and DNDi celebrate six years of collaboration in fighting malaria by distributing 200 million treatments of ASAQ

COMMUNIQUE DE PRESSE On World Malaria Day Sanofi and DNDi celebrate six years of collaboration in fighting malaria by distributing 200 million treatments of ASAQ Paris, France, and Geneva, Switzerland - April 25, 2013 - Sanofi (EURONEXT, SAN and NYSE; SNY) and the Drugs for Neglected Diseases initiative (DNDi), an independent... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[25/04/2013]

SANOFI-AVENTIS : Dans l’étude TOPIC, AUBAGIO® en une prise par jour retarde le développement d’une sclérose en plaques (SEP) cliniquement définie

COMMUNIQUÉ DE PRESSE Dans l'étude TOPIC, AUBAGIO(r) en une prise par jour retarde le développement d'une sclérose en plaques (SEP) cliniquement définie - Seul traitement oral commercialisé contre la SEP ayant obtenu des données positives chez les patients présentant un premier événement démyélinisant évocateur d'une SEP... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[25/04/2013]

SANOFI-AVENTIS : Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study

PRESS RELEASE Once-daily AUBAGIO(r) Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study - Only Marketed Oral MS Therapy with Positive Data in Patients who Experienced Initial Attack Suggestive of MS - Paris, France - April 25, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[24/04/2013]

SANOFI-AVENTIS : Sanofi Pasteur to Provide 1.7 Billion Doses of Oral Polio Vaccine from 2013 to 2017 for Polio Eradication

PRESS RELEASE Sanofi Pasteur to Provide 1.7 Billion Doses of Oral Polio Vaccine from 2013 to 2017 for Polio Eradication - Company also expands injectable polio vaccine production capacity to respond to the World Health Organization's endgame strategy - Lyon, France - April 24, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN... See more
 
Page : 1 - 2 - ... 6 - 7 - 8 - 9 - 10 - 11 - 12 - ...
Videos
Gestionnaires,
Emetteurs,
My favourite companies
Most read news of SANOFI-AVENTIS
Dissemination technology Webdisclosure.com - copyright 2020 SYMEX ECONOMICS all rights reserved